Latest Insider Transactions at Vyne Therapeutics Inc. (VYNE)
This section provides a real-time view of insider transactions for Vyne Therapeutics Inc. (VYNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VYNE Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VYNE Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 30
2024
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,901
+0.77%
|
$7,802
$2.1 P/Share
|
|
Sep 30
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
105
-0.07%
|
$105
$1.88 P/Share
|
|
Sep 30
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
685
-0.14%
|
$685
$1.88 P/Share
|
|
Sep 30
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
109
-0.08%
|
$109
$1.88 P/Share
|
|
Sep 30
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-0.06%
|
$84
$1.88 P/Share
|
|
Jul 01
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
935
-0.19%
|
$935
$1.92 P/Share
|
|
Jul 01
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
143
-0.1%
|
$143
$1.92 P/Share
|
|
Jul 01
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
138
-0.1%
|
$138
$1.92 P/Share
|
|
Jul 01
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-0.07%
|
$92
$1.92 P/Share
|
|
May 31
2024
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,429
+0.88%
|
$8,858
$2.16 P/Share
|
|
Apr 01
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-0.12%
|
$471
$3.08 P/Share
|
|
Apr 01
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
94
-0.07%
|
$282
$3.08 P/Share
|
|
Apr 01
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,004
-0.2%
|
$3,012
$3.08 P/Share
|
|
Apr 01
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
161
-0.11%
|
$483
$3.08 P/Share
|
|
Jan 02
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
161
-0.11%
|
$322
$2.28 P/Share
|
|
Jan 02
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-0.12%
|
$314
$2.28 P/Share
|
|
Jan 02
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
93
-0.07%
|
$186
$2.28 P/Share
|
|
Jan 02
2024
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,004
-0.2%
|
$2,008
$2.28 P/Share
|
|
Jan 01
2024
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+29.47%
|
-
|
|
Jan 01
2024
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+31.8%
|
-
|
|
Jan 01
2024
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+32.15%
|
-
|
|
Jan 01
2024
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+31.2%
|
-
|
|
Dec 13
2023
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+46.62%
|
-
|
|
Dec 13
2023
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+47.37%
|
-
|
|
Dec 13
2023
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+45.35%
|
-
|
|
Dec 13
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+41.78%
|
-
|
|
Nov 30
2023
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,284
+4.71%
|
$4,568
$2.81 P/Share
|
|
Nov 15
2023
|
Patrick G Lepore |
BUY
Open market or private purchase
|
Direct |
13,000
+26.28%
|
$39,000
$3.91 P/Share
|
|
Oct 02
2023
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,087
-13.56%
|
$3,261
$3.83 P/Share
|
|
Oct 02
2023
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,549
-16.3%
|
$25,647
$3.83 P/Share
|
|
Oct 02
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,154
-4.48%
|
$3,462
$3.83 P/Share
|
|
Oct 02
2023
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-11.56%
|
$3,552
$3.83 P/Share
|
|
Jun 30
2023
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
91
-1.12%
|
$364
$4.1 P/Share
|
|
Jun 30
2023
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
981
-1.84%
|
$3,924
$4.1 P/Share
|
|
Jun 30
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-0.61%
|
$628
$4.1 P/Share
|
|
Jun 30
2023
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-1.45%
|
$604
$4.1 P/Share
|
|
May 31
2023
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,766
+4.92%
|
$8,298
$3.46 P/Share
|
|
May 31
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
3,664
+12.39%
|
$10,992
$3.46 P/Share
|
|
Mar 31
2023
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
480
-4.42%
|
$1,440
$3.08 P/Share
|
|
Mar 31
2023
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
384
-4.52%
|
$1,152
$3.08 P/Share
|
|
Mar 31
2023
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,734
-5.12%
|
$8,202
$3.08 P/Share
|
|
Mar 31
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
478
-2.1%
|
$1,434
$3.08 P/Share
|
|
Mar 20
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Open market or private purchase
|
Direct |
10,000
+30.56%
|
$20,000
$2.5 P/Share
|
|
Mar 20
2023
|
Patrick G Lepore |
BUY
Open market or private purchase
|
Direct |
20,000
+46.01%
|
$40,000
$2.48 P/Share
|
|
Dec 31
2022
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,813
-0.79%
|
$0
$0.15 P/Share
|
|
Dec 31
2022
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,685
-0.99%
|
$0
$0.15 P/Share
|
|
Dec 31
2022
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
354
-0.2%
|
$0
$0.15 P/Share
|
|
Dec 31
2022
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,720
-0.77%
|
$0
$0.15 P/Share
|
|
Nov 30
2022
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
34,705
+3.13%
|
$0
$0.2 P/Share
|
|
Sep 30
2022
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
353
-0.2%
|
$0
$0.22 P/Share
|